Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1450 Bone Penetration in Hip Replacement Surgery
NCT02726438Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of afabicin in staphylococcal infection (2 arms), sponsored by Debiopharm. Primary endpoint: Bone to plasma ratio for Debio 1452. Started Apr 2016; status: completed.
02
Drugs
afabicin
03
Conditions
staphylococcal infection
Beyond the preview
Go deeper on NCT02726438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726438.